Skip to main content
Premium Trial:

Request an Annual Quote

Merz Partners with DiaGenic on Alzheimer's Biomarkers

NEW YORK (GenomeWeb News) – DiaGenic today said that it has licensed biomarkers for mild cognitive impairment to drug firm Merz Pharmaceuticals, which will use the biomarkers for recruiting patients for Alzheimer's disease drug trials.

Frankfurt am Main, Germany-based Merz also has an option to license non-exclusive rights to further biomarkers, under terms of the agreement. Financial details and further terms were not disclosed.

"We have already successfully identified biomarkers of prodromal Alzheimer's disease," DiaGenic CEO Erik Christensen said in a statement. "The agreement with Merz will enable us to accelerate our ongoing multicenter study by recruiting additional sites."

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.